**Supplemental Table Legends**

***Supplemental Table 1. UPMC 09-021 patient demographics.*** Detailed patient demographics from the UPMC 09-021 phase I clinical trial.

***Supplemental Table 2. Critical DC markers are not prognostic factors for overall survival or progression free survival in advanced melanoma patients.*** Univariate Cox regression analysis for associations between critical DC markers (MFI) on AdVTMM2 (n=35) assessed prior to patient administration at baseline and OS and PFS. The hazard ratio, significance values, and 95% Confidence Intervals for each of these markers are listed.